Caspase-8 Promotes C-Rel–Dependent Inflammatory Cytokine Expression and Resistance Against Toxoplasma Gondii
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Apoptotic Threshold Is Lowered by P53 Transactivation of Caspase-6
Apoptotic threshold is lowered by p53 transactivation of caspase-6 Timothy K. MacLachlan*† and Wafik S. El-Deiry*‡§¶ʈ** *Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, and Departments of ‡Medicine, §Genetics, ¶Pharmacology, and Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 Communicated by Britton Chance, University of Pennsylvania School of Medicine, Philadelphia, PA, April 23, 2002 (received for review January 11, 2002) Little is known about how a cell’s apoptotic threshold is controlled Inhibition of the enzyme reduces the sensitivity conferred by after exposure to chemotherapy, although the p53 tumor suppres- overexpression of p53. These results identify a pathway by which sor has been implicated. We identified executioner caspase-6 as a p53 is able to accelerate the apoptosis cascade by loading the cell transcriptional target of p53. The mechanism involves DNA binding with cell death proteases so that when an apoptotic signal is by p53 to the third intron of the caspase-6 gene and transactiva- received, programmed cell death occurs rapidly. tion. A p53-dependent increase in procaspase-6 protein level al- lows for an increase in caspase-6 activity and caspase-6-specific Materials and Methods Lamin A cleavage in response to Adriamycin exposure. Specific Western Blotting and Antibodies. Immunoblotting was carried out by inhibition of caspase-6 blocks cell death in a manner that correlates using mouse anti-human p53 monoclonal (PAb1801; Oncogene), with caspase-6 mRNA induction by p53 and enhances long-term rabbit anti-human caspase-3 (Cell Signaling, Beverly, MA), mouse survival in response to a p53-mediated apoptotic signal. -
Combination of the Natural Compound Periplocin and TRAIL Induce
Han et al. Journal of Experimental & Clinical Cancer Research (2019) 38:501 https://doi.org/10.1186/s13046-019-1498-z RESEARCH Open Access Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy Lujuan Han1†, Suli Dai1†, Zhirong Li1, Cong Zhang1, Sisi Wei1, Ruinian Zhao1, Hongtao Zhang2, Lianmei Zhao1* and Baoen Shan1* Abstract Background: Esophageal cancer is one of the most common malignant tumors in the world. With currently available therapies, only 20% ~ 30% patients can survive this disease for more than 5 years. TRAIL, a natural ligand for death receptors that can induce the apoptosis of cancer cells, has been explored as a therapeutic agent for cancers, but it has been reported that many cancer cells are resistant to TRAIL, limiting the potential clinical use of TRAIL as a cancer therapy. Meanwhile, Periplocin (CPP), a natural compound from dry root of Periploca sepium Bge, has been studied for its anti-cancer activity in a variety of cancers. It is not clear whether CPP and TRAIL can have activity on esophageal squamous cell carcinoma (ESCC) cells, or whether the combination of these two agents can have synergistic activity. Methods: We used MTS assay, flow cytometry and TUNEL assay to detect the effects of CPP alone or in combination with TRAIL on ESCC cells. The mechanism of CPP enhances the activity of TRAIL was analyzed by western blot, dual luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) assay. The anti-tumor effects and the potential toxic side effects of CPP alone or in combination with TRAIL were also evaluated in vivo. -
XIAP's Profile in Human Cancer
biomolecules Review XIAP’s Profile in Human Cancer Huailu Tu and Max Costa * Department of Environmental Medicine, Grossman School of Medicine, New York University, New York, NY 10010, USA; [email protected] * Correspondence: [email protected] Received: 16 September 2020; Accepted: 25 October 2020; Published: 29 October 2020 Abstract: XIAP, the X-linked inhibitor of apoptosis protein, regulates cell death signaling pathways through binding and inhibiting caspases. Mounting experimental research associated with XIAP has shown it to be a master regulator of cell death not only in apoptosis, but also in autophagy and necroptosis. As a vital decider on cell survival, XIAP is involved in the regulation of cancer initiation, promotion and progression. XIAP up-regulation occurs in many human diseases, resulting in a series of undesired effects such as raising the cellular tolerance to genetic lesions, inflammation and cytotoxicity. Hence, anti-tumor drugs targeting XIAP have become an important focus for cancer therapy research. RNA–XIAP interaction is a focus, which has enriched the general profile of XIAP regulation in human cancer. In this review, the basic functions of XIAP, its regulatory role in cancer, anti-XIAP drugs and recent findings about RNA–XIAP interactions are discussed. Keywords: XIAP; apoptosis; cancer; therapeutics; non-coding RNA 1. Introduction X-linked inhibitor of apoptosis protein (XIAP), also known as inhibitor of apoptosis protein 3 (IAP3), baculoviral IAP repeat-containing protein 4 (BIRC4), and human IAPs like protein (hILP), belongs to IAP family which was discovered in insect baculovirus [1]. Eight different IAPs have been isolated from human tissues: NAIP (BIRC1), BIRC2 (cIAP1), BIRC3 (cIAP2), XIAP (BIRC4), BIRC5 (survivin), BIRC6 (apollon), BIRC7 (livin) and BIRC8 [2]. -
Human RIPK1 Deficiency Causes Combined Immunodeficiency and Inflammatory Bowel Diseases
Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases Yue Lia,1, Marita Führerb,1, Ehsan Bahramia,1, Piotr Sochac, Maja Klaudel-Dreszlerc, Amira Bouzidia, Yanshan Liua, Anna S. Lehlea, Thomas Magga, Sebastian Hollizecka, Meino Rohlfsa, Raffaele Concaa, Michael Fieldd, Neil Warnere,f, Slae Mordechaig, Eyal Shteyerh, Dan Turnerh,i, Rachida Boukarij, Reda Belbouabj, Christoph Walzk, Moritz M. Gaidtl,m, Veit Hornungl,m, Bernd Baumannn, Ulrich Pannickeb, Eman Al Idrissio, Hamza Ali Alghamdio, Fernando E. Sepulvedap,q, Marine Gilp,q, Geneviève de Saint Basilep,q,r, Manfred Hönigs, Sibylle Koletzkoa,i, Aleixo M. Muisee,f,i,t,u, Scott B. Snapperd,i,v,w, Klaus Schwarzb,x,2, Christoph Kleina,i,2, and Daniel Kotlarza,i,2,3 aDr. von Hauner Children’s Hospital, Department of Pediatrics, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, 80337 Munich, Germany; bThe Institute for Transfusion Medicine, University of Ulm, 89081 Ulm, Germany; cDepartment of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children’s Memorial Health Institute, 04730 Warsaw, Poland; dDivision of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA 02115; eSickKids Inflammatory Bowel Disease Center, Research Institute, Hospital for Sick Children, Toronto, ON M5G1X8, Canada; fCell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON M5G1X8, Canada; gPediatric Gastroenterology, Hadassah University Hospital, Jerusalem 91120, Israel; hThe Juliet Keidan -
P53 and the Cathepsin Proteases As Co-Regulators of Cancer and Apoptosis
cancers Review Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis Surinder M. Soond 1,*, Lyudmila V. Savvateeva 1, Vladimir A. Makarov 1, Neonila V. Gorokhovets 1, Paul A. Townsend 2 and Andrey A. Zamyatnin, Jr. 1,3,4,* 1 Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Trubetskaya Str. 8-2, 119991 Moscow, Russia; [email protected] (L.V.S.); [email protected] (V.A.M.); gorokhovets_n_v@staff.sechenov.ru (N.V.G.) 2 Division of Cancer Sciences and Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and the NIHR Manchester Biomedical Research Centre, Manchester M13 9PL, UK; [email protected] 3 Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia 4 Department of Biotechnology, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sochi, Russia * Correspondence: [email protected] (S.M.S.); [email protected] (A.A.Z.J.) Received: 6 October 2020; Accepted: 19 November 2020; Published: 22 November 2020 Simple Summary: This article describes an emerging area of significant interest in cancer and cell death and the relationships shared by these through the p53 and cathepsin proteins. While it has been demonstrated that the p53 protein can directly induce the leakage of cathepsin proteases from the lysosome, directly triggering cell death, little is known about what factors set the threshold at which the lysosome can become permeabilized. It appears that the expression levels of cathepsin proteases may be central to this process, with some of them being transcriptionally regulated by p53. -
The Role of Caspase-2 in Regulating Cell Fate
cells Review The Role of Caspase-2 in Regulating Cell Fate Vasanthy Vigneswara and Zubair Ahmed * Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK; [email protected] * Correspondence: [email protected] Received: 15 April 2020; Accepted: 12 May 2020; Published: 19 May 2020 Abstract: Caspase-2 is the most evolutionarily conserved member of the mammalian caspase family and has been implicated in both apoptotic and non-apoptotic signaling pathways, including tumor suppression, cell cycle regulation, and DNA repair. A myriad of signaling molecules is associated with the tight regulation of caspase-2 to mediate multiple cellular processes far beyond apoptotic cell death. This review provides a comprehensive overview of the literature pertaining to possible sophisticated molecular mechanisms underlying the multifaceted process of caspase-2 activation and to highlight its interplay between factors that promote or suppress apoptosis in a complicated regulatory network that determines the fate of a cell from its birth and throughout its life. Keywords: caspase-2; procaspase; apoptosis; splice variants; activation; intrinsic; extrinsic; neurons 1. Introduction Apoptosis, or programmed cell death (PCD), plays a pivotal role during embryonic development through to adulthood in multi-cellular organisms to eliminate excessive and potentially compromised cells under physiological conditions to maintain cellular homeostasis [1]. However, dysregulation of the apoptotic signaling pathway is implicated in a variety of pathological conditions. For example, excessive apoptosis can lead to neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, whilst insufficient apoptosis results in cancer and autoimmune disorders [2,3]. Apoptosis is mediated by two well-known classical signaling pathways, namely the extrinsic or death receptor-dependent pathway and the intrinsic or mitochondria-dependent pathway. -
Essential Role of Survivin, an Inhibitor of Apoptosis Protein, in T Cell
Essential Role of Survivin, an Inhibitor of Apoptosis Protein, in T Cell Development, Maturation, and Homeostasis Zheng Xing,1 Edward M. Conway,2 Chulho Kang,1 and Astar Winoto1 1Department of Molecular and Cell Biology, Division of Immunology and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720 2Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, B-3000 Leuven, Belgium Abstract Survivin is an inhibitor of apoptosis protein that also functions during mitosis. It is expressed in all common tumors and tissues with proliferating cells, including thymus. To examine its role in apoptosis and proliferation, we generated two T cell–specific survivin-deficient mouse lines with deletion occurring at different developmental stages. Analysis of early deleting survivin mice showed arrest at the pre–T cell receptor proliferating checkpoint. Loss of survivin at a later stage resulted in normal thymic development, but peripheral T cells were immature and significantly reduced in number. In contrast to in vitro studies, loss of survivin does not lead to increased apoptosis. However, newborn thymocyte homeostatic and mitogen-induced proliferation of survivin-deficient T cells were greatly impaired. These data suggest that survivin is not essential for T cell apoptosis but is crucial for T cell maturation and proliferation, and survivin-mediated homeostatic expansion is an important physiological process of T cell development. Key words: proliferation • apoptosis • T cell development • survivin • IAP Introduction The thymus is the major organ of T lymphocyte maturation CD4 CD8 or CD4 CD8 (single positive [SP]) cells. and differentiation. During development, T cells have to These mature cells then migrate to the peripheral immune confront sequentially fateful decisions: the pre-TCR organs where they carry out their major function in defend- checkpoint, TCR chain rearrangements, positive selection, ing the body against foreign invasion. -
Proteases to Die For
Downloaded from genesdev.cshlp.org on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Proteases to die for Vincent Cryns1 and Junying Yuan2,3 1Center for Endocrinology, Metabolism and Molecular Medicine, Northwestern University School of Medicine, Chicago, Illinois 60611 USA; 2Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115 USA Apoptosis or programmed cell death (PCD) is a geneti- have identified two genes (ced-3 and ced-4) that are each cally regulated, cellular suicide mechanism that plays a required for the execution of cell death and one (ced-9) crucial role in development and in the defense of homeo- that inhibits cell death (Hengartner et al. 1992; Yuan and stasis. Cells respond to a variety of disparate signals by Horvitz 1992; Yuan et al. 1993). Mutational analyses of committing suicide through a series of dramatic but re- these genes in C. elegans have defined a sequential cell markably uniform events. Morphologically, cells under- death pathway. Inactivating mutations of ced-9 result in going apoptosis demonstrate nuclear/cytoplasmic con- inappropriate cell deaths, but only if both ced-3 and densation and membrane protrusions. These initial ced-4 are functional (Hengartner et al. 1992). Targeted changes are followed by fragmentation of the nuclear overexpression of either ced-4 or ced-3 induces cell contents and subsequent encapsulation of these frag- death, these cell deaths are inhibited by ced-9. In trans- ments into ‘‘apoptotic bodies’’ that are quickly and un- genic worms, maximal cell death induced by ced-4 over- obtrusively consumed by adjacent cells, thereby leaving expression requires ced-3, whereas ced-3-mediated cell little trace of the apoptotic cell’s prior existence (Kerr et death is independent of ced-4. -
Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy
Published OnlineFirst July 15, 2013; DOI: 10.1158/0008-5472.CAN-13-0036 Cancer Molecular and Cellular Pathobiology Research Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy Fred erique Vegran 1,5, Romain Mary1, Anne Gibeaud1,Celine Mirjolet2, Bertrand Collin4,6, Alexandra Oudot4, Celine Charon-Barra3, Laurent Arnould3, Sarab Lizard-Nacol1, and Romain Boidot1 Abstract Dysregulation in patterns of alternative RNA splicing in cancer cells is emerging as a significant factor in cancer pathophysiology. In this study, we investigated the little known alternative splice isoform survivin-3B (S-3B) that is overexpressed in a tumor-specific manner. Ectopic overexpression of S-3B drove tumorigenesis by facilitating immune escape in a manner associated with resistance to immune cell toxicity. This resistance was mediated by interaction of S-3B with procaspase-8, inhibiting death-inducing signaling complex formation in response to Fas/ Fas ligand interaction. We found that S-3B overexpression also mediated resistance to cancer chemotherapy, in this case through interactions with procaspase-6. S-3B binding to procaspase-6 inhibited its activation despite mitochondrial depolarization and caspase-3 activation. When combined with chemotherapy, S-3B targeting in vivo elicited a nearly eradication of tumors. Mechanistic investigations identified a previously unrecognized 7-amino acid region as responsible for the procancerous properties of survivin proteins. Taken together, our results defined S-3B as an important functional actor in tumor formation and treatment resistance. Cancer Res; 73(17); 1–11. Ó2013 AACR. Introduction that can induce the expression of five different transcripts with D Alternative splicing is an important mechanism for the different functions: survivin, survivin- Ex3, survivin-2B (5), a generation of the variety of proteins indispensable for cell survivin-3B (S-3B; ref. -
Bax Transmembrane Domain Interacts with Prosurvival Bcl-2 Proteins in Biological Membranes
Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes Vicente Andreu-Fernándeza,b,c, Mónica Sanchoa, Ainhoa Genovésa, Estefanía Lucendoa, Franziska Todtb, Joachim Lauterwasserb,d, Kathrin Funkb,d, Günther Jahreise, Enrique Pérez-Payáa,f,1, Ismael Mingarroc,2, Frank Edlichb,g,2, and Mar Orzáeza,2 aLaboratory of Peptide and Protein Chemistry, Centro de Investigación Príncipe Felipe, E-46012 Valencia, Spain; bInstitute for Biochemistry and Molecular Biology, University of Freiburg, 79104 Freiburg, Germany; cDepartament de Bioquímica i Biologia Molecular, Estructura de Recerca Interdisciplinar en Biotecnología i Biomedicina, Universitat de València, 46100 Burjassot, Spain; dFaculty of Biology, University of Freiburg, 79104 Freiburg, Germany; eDepartment of Biochemistry/Biotechnology, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany; fInstituto de Biomedicina de Valencia, Instituto de Biomedicina de Valencia–Consejo Superior de Investigaciones Científicas, 46010 Valencia, Spain; and gBIOSS, Centre for Biological Signaling Studies, University of Freiburg, 79104 Freiburg, Germany Edited by William F. DeGrado, School of Pharmacy, University of California, San Francisco, CA, and approved November 29, 2016 (received for review July 28, 2016) The Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, across bilayers via changes in the oligomeric state or protein con- apoptosis regulator) can commit cells to apoptosis via outer mito- formation (22–24). The Bax TMD targets fusion proteins to the chondrial membrane permeabilization. Bax activity is controlled in OMM; its deletion results in cytosolic Bax localization and impaired healthy cells by prosurvival Bcl-2 proteins. C-terminal Bax trans- Bax activity (25). Analysis of the active Bax membrane topology membrane domain interactions were implicated recently in Bax pore suggests that the TMD could play a central role in Bax oligomeri- formation. -
Targeting RIP Kinases in Chronic Inflammatory Disease
biomolecules Review Targeting RIP Kinases in Chronic Inflammatory Disease Mary Speir 1,2, Tirta M. Djajawi 1,2 , Stephanie A. Conos 1,2, Hazel Tye 1 and Kate E. Lawlor 1,2,* 1 Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia; [email protected] (M.S.); [email protected] (T.M.D.); [email protected] (S.A.C.); [email protected] (H.T.) 2 Department of Molecular and Translational Science, Monash University, Clayton, VIC 3168, Australia * Correspondence: [email protected]; Tel.: +61-85722700 Abstract: Chronic inflammatory disorders are characterised by aberrant and exaggerated inflam- matory immune cell responses. Modes of extrinsic cell death, apoptosis and necroptosis, have now been shown to be potent drivers of deleterious inflammation, and mutations in core repressors of these pathways underlie many autoinflammatory disorders. The receptor-interacting protein (RIP) kinases, RIPK1 and RIPK3, are integral players in extrinsic cell death signalling by regulating the production of pro-inflammatory cytokines, such as tumour necrosis factor (TNF), and coordinating the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome, which underpin patholog- ical inflammation in numerous chronic inflammatory disorders. In this review, we firstly give an overview of the inflammatory cell death pathways regulated by RIPK1 and RIPK3. We then discuss how dysregulated signalling along these pathways can contribute to chronic inflammatory disorders of the joints, skin, and gastrointestinal tract, and discuss the emerging evidence for targeting these RIP kinases in the clinic. Keywords: apoptosis; necroptosis; RIP kinases; chronic inflammatory disease; tumour necrosis factor; Citation: Speir, M.; Djajawi, T.M.; interleukin-1 Conos, S.A.; Tye, H.; Lawlor, K.E. -
The Combination of TPL2 Knockdown and Tnfα Causes Synthetic Lethality Via Caspase-8 Activation in Human Carcinoma Cell Lines
The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines Oksana B. Serebrennikovaa, Maria D. Paraskevopouloua, Elia Aguado-Frailea,1, Vasiliki Tarasliaa, Wenying Rena,2, Geeta Thapaa, Jatin Ropera,3, Keyong Dua,2, Carlo M. Croceb,c,4, and Philip N. Tsichlisa,b,c,4 aMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111; bDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210; and cThe Ohio State University Comprehensive Cancer Center, Columbus, OH 43210 Contributed by Carlo M. Croce, May 21, 2019 (sent for review January 29, 2019; reviewed by Emad S. Alnemri and Wafik El-Deiry) Most normal and tumor cells are protected from tumor necrosis subset of tumor cells and we delineate the relevant TPL2-regulated factor α (TNFα)-induced apoptosis. Here, we identify the MAP3 pathway(s). kinase tumor progression locus-2 (TPL2) as a player contributing TPL2 is an oncoprotein that is activated by provirus insertion to the protection of a subset of tumor cell lines. The combination in Moloney murine leukemia virus-induced rodent lymphomas of TPL2 knockdown and TNFα gives rise to a synthetic lethality and mammary tumor virus-induced mammary adenocarcinomas phenotype via receptor-interacting serine/threonine-protein ki- (13, 14). Expression of constitutively active TPL2 from a thymus- nase 1 (RIPK1)-dependent and -independent mechanisms. Whereas targeted transgene confirmed its oncogenic potential (15). Sub- wild-type TPL2 rescues